A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count: Fertility and assisted reproduction

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 117, Issue 7, 2010, Pages 853-862

  Jayaprakasan, K ^a   Hopkisson, J ^a   Campbell, B ^a   Johnson, I ^a   Thornton, J ^a   Raine Fenning, N ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antral follicle count; IVF ICSI outcome; Ovarian response; Predicted normal responders; Randomised controlled trial; Recombinant gonadotrophin

Indexed keywords

RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG RESPONSE; FEMALE; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; MAJOR CLINICAL STUDY; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; BUSERELIN; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; NAFARELIN; OOCYTE RETRIEVAL; OOCYTES; OVARIAN FOLLICLE; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77952265316     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2010.02545.x     Document Type: Article

References (35)

1. Arslan M, Bocca S, Mirkin S, Barroso G, Stadtmauer L, Oehninger S. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril 2005 84 : 555 569.
2. Dorn C. FSH: what is the highest dose for ovarian stimulation that makes sense on an evidence-based level? Reprod Biomed Online 2005 11 : 555 561.
3. Yong PY, Brett S, Baird DT, Thong KJ. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertil Steril 2003 79 : 308 315.
4. Pruksananonda K, Suwajanakorn S, Sereepapong W, Virutamasen P. Comparison of two different fixed doses of follitropin-beta in controlled ovarian hyperstimulation: a prospective randomized, double blind clinical trial. J Med Assoc Thai 2004 87 : 1151 1155.
5. Tan SL, Child TJ, Cheung AP, Fluker MR, Yuzpe A, Casper R, et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment. J Assist Reprod Genet 2005 22 : 81 8.
6. Out HJ, Braat DD, Lintsen BM, et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum Reprod 2000 15 : 29 35.
7. Out HJ, David I, Ron-El R, et al. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum Reprod 2001 16 : 1104 1109.
8. Out HJ, Lindenberg S, Mikkelsen AL, et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod 1999 14 : 622 627.
9. Hoomans EH, Mulder BB. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. J Assist Reprod Genet 2002 19 : 470 476.
10. Bancsi LF, Broekmans FJ, Mol BW, Habbema JD, te Velde ER. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril 2003 79 : 1091 1100.
11. Bancsi LF, Huijs AM, den Ouden CT, et al. Basal follicle-stimulating hormone levels are of limited value in predicting ongoing pregnancy rates after in vitro fertilization. Fertil Steril 2000 73 : 552 557.
12. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003 9 : 505 514.
13. MacDougall MJ, Tan SL, Jacobs HS. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 1992 7 : 597 600.
14. Sahu B, Ozturk O, Ranierri M, Serhal P. Comparison of oocyte quality and intracytoplasmic sperm injection outcome in women with isolated polycystic ovaries or polycystic ovarian syndrome. Arch Gynecol Obstet 2008 277 : 239 244.
15. Hendriks DJ, Mol BW, Bancsi LF, Te Velde ER, Broekmans FJ. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril 2005 83 : 291 301.
16. Bancsi LF, Broekmans FJ, Eijkemans MJ, de Jong FH, Habbema JD, te Velde ER. Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 2002 77 : 328 336.
17. Jayaprakasan K, Hilwah N, Kendall NR, et al. Does 3D ultrasound offer any advantage in the pretreatment assessment of ovarian reserve and prediction of outcome after assisted reproduction treatment? Hum Reprod 2007 22 : 1932 1941.
18. Jayaprakasan K, Jayaprakasan R, Al-Hasie HA, et al. Can quantitative three-dimensional power Doppler angiography be used to predict ovarian hyperstimulation syndrome? Ultrasound Obstet Gynecol 2009 33 : 583 591.
19. Raine-Fenning NJ, Campbell BK, Clewes JS, Johnson IR. The interobserver reliability of ovarian volume measurement is improved with three-dimensional ultrasound, but dependent upon technique. Ultrasound Med Biol 2003 29 : 1685 1690.
20. Garcia-Velasco JA, Isaza V, Quea G, Pellicer A. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertil Steril 2006 85 : 547 554.
21. Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 1991 6 : 1395 1399.
22. Brinsden PR. Textbook of In Vitro Fertilisation and Assisted Reproduction.
23. Van Royen E, Mangelschots K, De Neubourg D, et al. Characterization of a top quality embryo, a step towards single-embryo transfer. Hum Reprod 1999 14 : 2345 2349.
24. Fauser BC, Diedrich K, Devroey P. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 2008 14 : 1 14.
25. Schipper I, Hop WC, Fauser BC. The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development. J Clin Endocrinol Metab 1998 83 : 1292 1298.
26. van der Gaast MH, Eijkemans MJ, van der Net JB, et al. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online 2006 13 : 476 480.
27. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006 12 : 685 718.
28. Zaidi J, Barber J, Kyei-Mensah A, Bekir J, Campbell S, Tan SL. Relationship of ovarian stromal blood flow at the baseline ultrasound scan to subsequent follicular response in an in vitro fertilization program. Obstet Gynecol 1996 88 : 779 784.
29. Greb RR, Behre HM, Simoni M. Pharmacogenetics in ovarian stimulation - current concepts and future options. Reprod Biomed Online 2005 11 : 589 600.
30. Loutradis D, Patsoula E, Minas V, et al. FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs. J Assist Reprod Genet 2006 23 : 177 184.
31. Jayaprakasan K, Campbell BK, Clewes JS, Johnson IR, Raine-Fenning NJ. Three-dimensional ultrasound improves the interobserver reliability of antral follicle counts and facilitates increased clinical work flow. Ultrasound Obstet Gynecol 2008 31 : 439 444.
32. Nelson SM, Yates RW, Lyall H, et al. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009 24 : 867 875.
33. Latin-American Puregon IVF Study Group. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization. Fertil Steril 2001 76 : 950 956.
34. Olivennes F, Howles CM, Borini A, et al. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 2009 18 : 195 204.
35. Verberg MF, Eijkemans MJ, Macklon NS, et al. The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis. Hum Reprod Update 2009 15 : 5 12.